deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02522780

Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis

Sponsor: Ferring Pharmaceuticals

Conditions Ulcerative Colitis
Interventions Mesalamine Placebo
Updated 15 times since 2017 Last updated: Nov 5, 2021 Started: Feb 1, 2016 Primary completion: Sep 19, 2018 Completion: Sep 19, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02522780, this PHASE3 trial focuses on Ulcerative Colitis and remains completed. Sponsored by Ferring Pharmaceuticals, it has been updated 15 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Nov 2017 · 5 months · monthly snapshot~Nov 2017 – ~Apr 2018 · 5 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Oct 2019 · 11 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE3

  2. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE3

  3. Nov 2018 — Oct 2019 [monthly]

    Completed PHASE3

  4. Oct 2018 — Nov 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Nov 2017 — Apr 2018 [monthly]

    Recruiting PHASE3

  8. Jun 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  9. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ferring Pharmaceuticals
Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belgrade, Serbia , Bern, Switzerland , Bialystok, Poland , Budapest, Hungary , Chernivtsi, Ukraine , Chihuahua City, Mexico , Christiansburg, United States , Częstochowa, Poland , Daugavpils, Latvia , Debrecen, Hungary and 60 more locations